KRAS Inhibition in Non-Small Cell Lung Cancer with Central Nervous System Involvement: Current Evidence and Future Directions
Even with recent progress in treatment, brain metastases continue to pose a significant challenge in managing KRAS-mutant non-small cell lung cancer. Among currently available agents, adagrasib has shown encouraging intracranial activity and CNS penetration, and rational combination strategies are being explored to overcome resistance. Ongoing research should prioritize CNS-specific endpoints and integrated treatment approaches tailored to patients with brain involvement. .
Authors
- Humberto Fernandes (ORCID: https://orcid.org/0000-0002-0989-7593)
- Rafael Alvim Pereira (ORCID: https://orcid.org/0009-0000-3968-6618)
- Milena Tumelero
- Christian Oliveira
- Gabriel Lenz
Publication Details
- Journal
- Oncology Research and Treatment
- Published
- 2026-02-16
- DOI
- https://doi.org/10.1159/000550885
- Primary Topic
- Protein Kinase Regulation and GTPase Signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.00